

Antibody Drug Conjugates (ADCs): Advancements in the Treatment of Solid Tumors

On-demand presentations available from 09:00 CET, 22 September 2020

Live Q&A discussion to be held on Monday, 28 September 2020 from 17:00 to 17:30 CET

Objectives

- To update on the current treatment landscape surrounding ADCs in solid tumors
- To educate on recent innovations in ADC technology
- To share the clinical experience with novel ADCs in solid tumors to date

Pasi Jänne, MD, PhD

Dana-Farber Cancer Institute,
Boston, United States

Kanwal Raghav, MD

University of Texas
MD Anderson Cancer Center,
Houston, United States

Javier Cortes, MD, PhD

IOB Institute of Oncology, Quiron Group,
Madrid & Barcelona, Spain

Agenda

On-demand presentations available from 09:00 CET, 22 September 2020

5 min	Welcome and Introduction	Pasi Jänne, MD, PhD
20 min	ADCs as a Technologically Advanced Treatment Approach in Solid Tumors	Pasi Jänne, MD, PhD
20 min	Current Clinical Experience With Innovative ADCs in Breast Cancer	Javier Cortes, MD, PhD
20 min	Latest Findings From Clinical Trials in Lung Cancer With Technologically Advanced ADCs	Pasi Jänne, MD, PhD
20 min	Recent Clinical Findings With Novel ADCs in Colorectal and Gastric Cancer	Kanwal Raghav, MD
5 min	Summary and Close	Pasi Jänne, MD, PhD

Live Q&A discussion to be held on Monday, 28 September 2020 from 17:00 to 17:30 CET

30 min	Interactive Q&A/Panel Discussion	All faculty members
--------	---	----------------------------